Certified Researchers

Parathyroid Disorders Market Summary

As per Market Research Future analysis, the Parathyroid Disorders Market Size was estimated at 1.99 USD Billion in 2024. The Parathyroid Disorders industry is projected to grow from 2.106 USD Billion in 2025 to 3.704 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.81% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Parathyroid Disorders Market is experiencing notable growth driven by technological advancements and increasing awareness.

North America remains the largest market for parathyroid disorders, driven by advanced healthcare infrastructure and high prevalence rates.
The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and increasing patient populations.
Primary hyperparathyroidism continues to dominate the market, while secondary hyperparathyroidism is witnessing rapid growth due to heightened awareness and screening initiatives.
Key market drivers include the rising incidence of parathyroid disorders and technological advancements in treatment options, which are enhancing patient outcomes.

Market Size & Forecast

2024 Market Size	1.99 (USD Billion)
2035 Market Size	3.704 (USD Billion)
CAGR (2025 - 2035)	5.81%

Major Players

Amgen (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Novartis (CH), Sanofi (FR), Teva Pharmaceutical Industries (IL), AbbVie (US), Mylan (US)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Parathyroid Disorders Market Trends

The Parathyroid Disorders Market is currently experiencing notable transformations driven by advancements in medical technology and an increasing awareness of parathyroid conditions. The rise in diagnostic capabilities, particularly through imaging techniques and laboratory tests, has enhanced the identification of disorders such as hyperparathyroidism and hypoparathyroidism. This heightened awareness among healthcare professionals and patients alike is likely to lead to earlier interventions, which may improve patient outcomes. Furthermore, the growing prevalence of chronic kidney disease, which is often associated with parathyroid dysfunction, appears to be influencing the demand for effective treatment options. In addition, the market is witnessing a shift towards personalized medicine, where therapies are tailored to individual patient profiles. This trend is supported by ongoing research into the genetic and molecular underpinnings of parathyroid disorders, suggesting that future treatments may become more targeted and effective. The integration of telemedicine into patient care is also emerging as a significant factor, as it facilitates remote monitoring and consultations, thereby enhancing access to specialized care. Overall, the Parathyroid Disorders Market is poised for growth, driven by innovation and a deeper understanding of these complex conditions.

Advancements in Diagnostic Technologies

The Parathyroid Disorders Market is benefiting from significant improvements in diagnostic technologies. Enhanced imaging techniques and laboratory tests are enabling earlier and more accurate detection of parathyroid disorders. This trend is likely to facilitate timely interventions, which may lead to better patient outcomes.

Shift Towards Personalized Medicine

There is a growing emphasis on personalized medicine within the Parathyroid Disorders Market. Research into the genetic and molecular aspects of these disorders suggests that future treatments could be tailored to individual patient needs, potentially increasing their effectiveness and safety.

Integration of Telemedicine

The incorporation of telemedicine into the management of parathyroid disorders is becoming increasingly prevalent. This approach allows for remote consultations and monitoring, improving access to specialized care and enabling more efficient management of patient health.

Parathyroid Disorders Market Drivers

Regulatory Support for New Therapies

Regulatory bodies are playing a pivotal role in shaping the Parathyroid Disorders Market by facilitating the approval of new therapies and diagnostic tools. Streamlined regulatory processes and incentives for orphan drugs are encouraging the development of treatments specifically targeting parathyroid disorders. This supportive regulatory environment not only expedites the availability of innovative solutions but also instills confidence in investors and stakeholders. As more therapies gain approval, the Parathyroid Disorders Market is likely to expand, providing patients with access to cutting-edge treatments that address their specific needs.

Rising Incidence of Parathyroid Disorders

The increasing prevalence of parathyroid disorders, such as primary hyperparathyroidism and secondary hyperparathyroidism, is a notable driver for the Parathyroid Disorders Market. Studies indicate that the incidence of primary hyperparathyroidism has risen significantly, particularly among postmenopausal women, with estimates suggesting that it affects approximately 1 in 500 individuals. This growing patient population necessitates enhanced diagnostic and therapeutic options, thereby propelling market growth. Furthermore, the aging population is likely to contribute to the rise in parathyroid disorders, as older adults are more susceptible to these conditions. As awareness increases and more individuals seek treatment, the demand for innovative solutions in the Parathyroid Disorders Market is expected to escalate.

Increased Awareness and Screening Initiatives

Heightened awareness regarding parathyroid disorders among healthcare professionals and the general public is a critical driver for the Parathyroid Disorders Market. Educational campaigns and screening initiatives have led to earlier diagnosis and treatment of these conditions. For instance, the implementation of routine serum calcium and parathyroid hormone level testing in at-risk populations has facilitated timely intervention. This proactive approach not only improves patient outcomes but also contributes to market growth by increasing the number of diagnosed cases. As awareness continues to spread, the Parathyroid Disorders Market is likely to experience a surge in demand for diagnostic and therapeutic solutions.

Growing Investment in Research and Development

The Parathyroid Disorders Market is witnessing a surge in investment directed towards research and development. Pharmaceutical companies and research institutions are increasingly focusing on understanding the pathophysiology of parathyroid disorders, which may lead to the discovery of novel therapeutic targets. This influx of funding is expected to accelerate the development of innovative treatments and diagnostic tools. Moreover, collaborations between academia and industry are fostering a conducive environment for breakthroughs in the management of parathyroid disorders. As R&D efforts intensify, the Parathyroid Disorders Market is poised for significant advancements, ultimately benefiting patients and healthcare providers alike.

Technological Advancements in Treatment Options

Innovations in treatment modalities for parathyroid disorders are transforming the landscape of the Parathyroid Disorders Market. The advent of minimally invasive surgical techniques, such as video-assisted parathyroidectomy, has improved patient outcomes and reduced recovery times. Additionally, the development of novel pharmacological agents, including calcimimetics, has provided alternative treatment options for patients who are not candidates for surgery. These advancements not only enhance the efficacy of treatment but also expand the therapeutic options available to healthcare providers. As these technologies continue to evolve, they are likely to drive growth in the Parathyroid Disorders Market, catering to a broader range of patient needs.

Market Segment Insights

By Type of Disorder: Primary Hyperparathyroidism (Largest) vs. Secondary Hyperparathyroidism (Fastest-Growing)

The Parathyroid Disorders Market showcases a diverse array of conditions, with Primary Hyperparathyroidism standing as the largest segment due to its higher prevalence and extensive recognition. This disorder is primarily caused by an overproduction of parathyroid hormone (PTH), leading to elevated calcium levels in the blood. In contrast, Secondary Hyperparathyroidism, while having a smaller market share, is emerging rapidly as a critical focus for therapeutic interventions caused primarily by renal failure, which triggers the overactivity of the parathyroid glands to compensate for low calcium levels. Growth trends in the Parathyroid Disorders Market indicate a significant increase in awareness and diagnosis of Secondary Hyperparathyroidism, making it the fastest-growing segment as healthcare professionals seek to address its complications. The rising incidence of chronic kidney diseases is contributing to this trend, driving advancements in treatment modalities and healthcare policies aimed at early detection and management. Moreover, the increasing investment in research and development for targeted therapies and health technologies is expected to bolster the growth prospects of both Primary and Secondary Hyperparathyroidism, reshaping the market dynamics.

Primary Hyperparathyroidism (Dominant) vs. Secondary Hyperparathyroidism (Emerging)

Primary Hyperparathyroidism is characterized by excessive secretion of parathyroid hormones, leading to hypercalcemia, which is prevalent among postmenopausal women and often diagnosed incidentally. This segment, being dominant, benefits from established treatment pathways, including surgical options and medical management, which provides patients with effective symptom relief. In contrast, Secondary Hyperparathyroidism, caused predominantly by chronic kidney disease, represents an emerging segment that is gaining attention for its unique treatment challenges. It typically requires calcium and vitamin D supplementation to manage associated minerals, emphasizing the trends toward more sophisticated therapeutic strategies. The growing acknowledgment of the disease's impact has spurred research into new pharmacological agents aiming to revolutionize its management.

By Treatment Type: Medications (Largest) vs. Surgery (Fastest-Growing)

In the Parathyroid Disorders Market, the treatment type segment is mainly dominated by medications, which account for the largest share of the market. These include various pharmacological options that help manage the symptoms and underlying causes of parathyroid disorders. Surgery follows as a significant segment as well, utilized primarily for patients requiring persistent management under clinical supervision due to severe conditions. The increasing prevalence of parathyroid diseases contributes to a robust demand for both medications and surgical interventions. Growth trends in the Parathyroid Disorders Market are being largely driven by advancements in surgical techniques and the development of new pharmaceutical treatments. Medications remain a staple for initial treatment, but surgery is emerging swiftly as a favored option, particularly with more patients opting for definitive solutions. Furthermore, the rise in awareness of parathyroid disorders and improved diagnostic capabilities are helping to propel the growth of these segments significantly over the forecast period.

Medications (Dominant) vs. Surgery (Emerging)

Medications represent the dominant treatment option in the Parathyroid Disorders Market due to their effectiveness in managing symptoms and preventing complications. Patients often start with this approach, using drugs like calcimimetics and vitamin D analogs. On the other hand, surgery is seen as an emerging intervention, especially for patients who do not respond adequately to medication or present severe symptoms. Advances in minimally invasive techniques are making surgical procedures more accessible and less intimidating for patients. As awareness and diagnosis of parathyroid conditions improve, it is expected that surgical referrals will increase, thus elevating its status in the market further. Collectively, both segments demonstrate significant value in treating parathyroid disorders, each serving distinct patient needs.

By Diagnosis Method: Blood Tests (Largest) vs. Imaging Tests (Fastest-Growing)

Within the 'Diagnosis Method' segment of the Parathyroid Disorders Market, blood tests currently hold the largest market share due to their widespread usage and effectiveness in diagnosing parathyroid disorders. Imaging tests, while smaller in market share, are rapidly gaining traction as innovative technologies enhance their accuracy and patient comfort. The adoption of these methods is increasingly favoring a more comprehensive approach to diagnosis, driven by the necessity for precise and timely identification of parathyroid diseases.

Blood Tests (Dominant) vs. Imaging Tests (Emerging)

Blood tests serve as the dominant method in diagnosing parathyroid disorders, providing vital information regarding hormone levels and calcium metabolism. Their established reliability and ease of access contribute to their widespread adoption. Conversely, imaging tests, such as ultrasound and CT scans, represent the emerging facet within diagnosis methodologies. These tests are becoming essential for detecting structural anomalies in the parathyroid glands, driven by advancements in imaging technology and an increasing emphasis on non-invasive procedures. Together, these methods underscore a shifting paradigm towards integrated diagnostic strategies in healthcare.

By Patient Age Group: Adults (Largest) vs. Elderly (Fastest-Growing)

In the Parathyroid Disorders Market, the patient age group segment is comprised primarily of Adults, who currently hold the largest market share due to higher occurrences of parathyroid disorders within this demographic. Adults typically experience a range of parathyroid abnormalities such as primary hyperparathyroidism, which significantly influences treatment patterns and healthcare resource allocation. By comparison, the Elderly segment, while smaller in market share, is rapidly gaining traction as the aging population increasingly presents with parathyroid-related health issues. The growth trends within this segment are driven by an aging population and increasing awareness of parathyroid disorders among healthcare providers. With advancements in diagnostic techniques and management options for the Elderly, this segment is showing promising growth potential. Additionally, the rise in lifestyle-related diseases among Adults is prompting more frequent screenings and treatments, contributing to a continuous and evolving understanding of parathyroid disorders across all age groups.

Adults (Dominant) vs. Elderly (Emerging)

Adults represent the dominant age group in the Parathyroid Disorders Market due to the prevalence of conditions such as primary hyperparathyroidism. This demographic often experiences complications related to the management of the disorder, driving demand for effective treatment solutions. In contrast, the Elderly population is emerging as a significant focus for healthcare providers, characterized by an increasing incidence of parathyroid disease. As the population ages, healthcare systems are adapting to better address the unique challenges faced by older patients, who may present with multiple comorbidities and require tailored therapeutic approaches. This shift in focus highlights the necessity for ongoing research and innovation in treatment options suitable for diverse patient profiles.

Get more detailed insights about Parathyroid Disorders Market

Request Free Sample

Regional Insights

The Regional segmentation of the Global Parathyroid Disorders Market indicates a robust growth trajectory across multiple regions, driven by the increasing prevalence of parathyroid disorders and advancements in treatment options. In 2024, North America leads the market with an impressive value of 0.9 USD Billion, projected to rise significantly to 1.7 USD Billion by 2035, making it a dominant player in the Global Parathyroid Disorders Market revenue landscape. Europe follows closely, with a market value of 0.6 USD Billion in 2024 and an expected growth to 1.1 USD Billion by 2035, showcasing strong advancements in healthcare infrastructure and increased awareness.

The APAC region, though currently smaller with a value of 0.25 USD Billion in 2024, is set for considerable growth to 0.55 USD Billion by 2035, driven by rising healthcare expenditures and a growing geriatric population. South America, projected at 0.1 USD Billion in 2024, is anticipated to gain traction, reaching 0.2 USD Billion by 2035, primarily due to improving access to healthcare.

Meanwhile, the Middle East and Africa (MEA) market is valued at 0.14 USD Billion in 2024, growing to 0.25 USD Billion by 2035, reflecting significant investments in healthcare systems in the region.Overall, the Global Parathyroid Disorders Market data illustrates a promising landscape, with North America and Europe holding the majority share due to better healthcare access and innovative treatment methodologies.

Parathyroid Disorders Market Regional Image

Key Players and Competitive Insights

The Global Parathyroid Disorders Market is characterized by a competitive landscape that is continuously evolving due to advancements in medical research and a growing focus on targeted therapies. As parathyroid disorders become more prevalent, pharmaceutical companies are investing heavily in the development of innovative treatment options to address the specific needs of patients suffering from these conditions. Competition is marked by the entry of various players into the market; each aims to capture a share through unique offerings and strategic partnerships. The market is defined by the introduction of next-generation therapies, which promise improved efficacy and safety profiles. As companies navigate regulatory landscapes and consumer demands, understanding competitive positioning and the unique value propositions of each player becomes crucial for maintaining market share and driving growth.AbbVie is recognized as a significant player in the Global Parathyroid Disorders Market, leveraging its extensive experience in biopharmaceuticals to deliver innovative treatments. Known for its strong research and development capabilities, AbbVie focuses on developing targeted therapies that tackle parathyroid disorders specifically. The company's established presence in the global market is underscored by its commitment to patient-centric solutions and its robust pipeline that often features collaborations with academic institutions and other healthcare entities. AbbVie's strengths lie in its comprehensive understanding of the complex biology associated with parathyroid disorders, allowing it to position itself effectively within the competitive landscape. The company's well-resourced infrastructure supports its ability to navigate regulatory challenges efficiently, lending further credibility to its claims of quality and innovation in its offerings.Eli Lilly has made notable strides in the Global Parathyroid Disorders Market through its diversified portfolio of key products aimed at treating various endocrine disorders, including those affecting the parathyroid gland. The company’s market presence is bolstered by its commitment to research and development, particularly in the field of hormone-related therapies. Eli Lilly’s strengths are amplified by its strategic approach towards mergers and acquisitions, which has enabled it to enhance its product offerings and expand its technological capabilities in the global arena. The company continuously seeks to improve patient outcomes through innovative treatments that demonstrate both efficacy and safety. As part of its business strategy, Eli Lilly actively engages in collaborative partnerships, allowing it to tap into new markets and leverage expertise in parathyroid disorders, ultimately reinforcing its position as a key player in this specialized field.

Key Companies in the Parathyroid Disorders Market include

Industry Developments

The Global Parathyroid Disorders Market has seen notable developments recently, with increased investment in research and development from key players such as AbbVie, Eli Lilly, and Novartis, focusing on novel therapeutic approaches for conditions like hyperparathyroidism. In October 2023, GSK announced advancements in their parathyroid hormone candidates, contributing to the competitive landscape. The market is experiencing growth due to rising incidences of parathyroid disorders, influencing pharmaceutical companies to enhance their product portfolios. In September 2023, Teva Pharmaceutical Industries expanded its operations to include parathyroid disorder treatments and reported a significant growth in market valuation, further bolstering the competitive environment.

Additionally, there have been no major mergers or acquisitions reported in this sector involving the specified companies over the last few months, reflecting a period of stable development. Overall, the combination of increasing product advancements by companies such as F. Hoffmann-La Roche and Amgen, coupled with the growing awareness about parathyroid disorders, is shaping the global market landscape significantly.

Future Outlook

Parathyroid Disorders Market Future Outlook

The Parathyroid Disorders Market is projected to grow at a 5.81% CAGR from 2025 to 2035, driven by advancements in diagnostics, increasing prevalence, and innovative treatment options.

New opportunities lie in:

Development of targeted therapies for hyperparathyroidism Expansion of telehealth services for patient management Investment in AI-driven diagnostic tools for early detection

By 2035, the market is expected to achieve substantial growth, reflecting evolving treatment paradigms and increased patient access.

Market Segmentation

Parathyroid Disorders Market Treatment Type Outlook

Medications
Surgery
Radiation Therapy
Observation

Parathyroid Disorders Market Diagnosis Method Outlook

Blood Tests
Imaging Tests
Biopsies

Parathyroid Disorders Market Type of Disorder Outlook

Primary Hyperparathyroidism
Secondary Hyperparathyroidism
Tertiary Hyperparathyroidism

Parathyroid Disorders Market Patient Age Group Outlook

Children
Adults
Elderly

Report Scope

MARKET SIZE 2024	1.99(USD Billion)
MARKET SIZE 2025	2.106(USD Billion)
MARKET SIZE 2035	3.704(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.81% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Amgen (US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Novartis (CH), Sanofi (FR), Teva Pharmaceutical Industries (IL), AbbVie (US), Mylan (US)
Segments Covered	Type of Disorder, Treatment Type, Diagnosis Method, Patient Age Group, Regional
Key Market Opportunities	Advancements in minimally invasive surgical techniques enhance treatment options in the Parathyroid Disorders Market.
Key Market Dynamics	Rising prevalence of parathyroid disorders drives demand for innovative treatment options and advanced diagnostic technologies.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Parathyroid Disorders Companies

FAQs

What is the projected market valuation for the Parathyroid Disorders Market in 2035?

The projected market valuation for the Parathyroid Disorders Market in 2035 is 3.704 USD Billion.

What was the market valuation for the Parathyroid Disorders Market in 2024?

The overall market valuation for the Parathyroid Disorders Market was 1.99 USD Billion in 2024.

What is the expected CAGR for the Parathyroid Disorders Market from 2025 to 2035?

The expected CAGR for the Parathyroid Disorders Market during the forecast period 2025 - 2035 is 5.81%.

Which companies are considered key players in the Parathyroid Disorders Market?

Key players in the Parathyroid Disorders Market include Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Novartis, Sanofi, Teva Pharmaceutical Industries, AbbVie, and Mylan.

What are the projected revenues for Primary Hyperparathyroidism by 2035?

The projected revenue for Primary Hyperparathyroidism is expected to reach between 1.5 USD Billion by 2035.

How does the revenue for Secondary Hyperparathyroidism compare to Tertiary Hyperparathyroidism in 2035?

By 2035, Secondary Hyperparathyroidism is projected to generate up to 1.2 USD Billion, whereas Tertiary Hyperparathyroidism is expected to reach 1.0 USD Billion.

What treatment type is expected to generate the highest revenue in the Parathyroid Disorders Market by 2035?

Medications are anticipated to generate the highest revenue, projected to reach 1.5 USD Billion by 2035.

What is the expected revenue for blood tests as a diagnostic method by 2035?

Blood tests are projected to generate up to 1.5 USD Billion in revenue by 2035.

Which patient age group is expected to contribute the most to the market by 2035?

Adults are expected to contribute the most, with projected revenues reaching 2.0 USD Billion by 2035.

What is the anticipated revenue for radiation therapy in the treatment of parathyroid disorders by 2035?

Radiation therapy is projected to generate between 0.5 USD Billion by 2035.

Author

Author

Vikita Thakur

Senior Research Analyst

She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.

Co-Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

Certified Researchers

Customize Report

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed endocrinology and nephrology journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, World Health Organization (WHO) Global Health Observatory, International Society of Nephrology (ISN), American Association of Clinical Endocrinology (AACE), Endocrine Society, Kidney Disease: Improving Global Outcomes (KDIGO), European Renal Association (ERA), National Kidney Foundation (NKF), EU Eurostat Health Database, and national health ministry reports from key markets (US HHS, UK NHS Digital, Japan MHLW, China NHC). These sources were used to collect disease prevalence statistics, regulatory approval data for calcimimetics and vitamin D analogs, clinical safety studies, CKD-mineral and bone disorder (CKD-MBD) treatment guidelines, demographic trends, and market landscape analysis for primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism treatment modalities including medications, surgical interventions, and diagnostic technologies.

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Product Development, regulatory affairs chiefs, and commercial directors from parathyroid disorder pharmaceutical manufacturers (Amgen, Eli Lilly, AbbVie, Novartis, Sanofi, Teva) and OEMs. Demand-side sources included procurement leads from academic medical centers, specialty endocrinology clinics, hospitals, and integrated healthcare networks, as well as board-certified endocrinologists, nephrologists, head and neck specialists, and medical directors from dialysis centers. The market segmentation was validated across disorder types (primary, secondary, and tertiary hyperparathyroidism), the calcimimetic and vitamin D analog pipeline timelines were confirmed, and insights were gathered on the clinical adoption patterns of cinacalcet and etelcalcetide, pricing strategies for PTH monitoring diagnostics, and reimbursement dynamics for parathyroidectomy procedures through primary research studies.

Primary Respondent Breakdown:

Table

Category Breakdown

By Designation C-level Primaries (32%), Director Level (30%), Others (38%)

By Region North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Market Size Estimation

Global market valuation was derived through revenue mapping and patient volume analysis. The methodology included:

Identification of 35+ key pharmaceutical and diagnostic manufacturers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across calcimimetics (cinacalcet, etelcalcetide), vitamin D analogs (calcitriol, paricalcitol, doxercalciferol), phosphate binders, and surgical treatment categories

Analysis of reported and modeled annual revenues specific to parathyroid disorder treatment portfolios

Coverage of manufacturers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (patient volume × ASP by country/region, segmented by primary vs. secondary hyperparathyroidism) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations across medications, surgery, radiation therapy, and observation treatment types

This methodology framework aligns with the specific market segments identified in the report: Type of Disorder (Primary Hyperparathyroidism, Secondary Hyperparathyroidism, Tertiary Hyperparathyroidism), Treatment Type (Medications, Surgery, Radiation Therapy, Observation), Diagnosis Method (Blood Tests, Imaging Tests, Biopsies), Patient Age Group (Children, Adults, Elderly), and Regional markets (North America, Europe, Asia-Pacific, South America, Middle East & Africa).